Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $48.0 million.

  • Lyra Therapeutics' Total Liabilities fell 1737.28% to $48.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.0 million, marking a year-over-year decrease of 1737.28%. This contributed to the annual value of $54.8 million for FY2024, which is 295.6% up from last year.
  • According to the latest figures from Q3 2025, Lyra Therapeutics' Total Liabilities is $48.0 million, which was down 1737.28% from $51.0 million recorded in Q2 2025.
  • Lyra Therapeutics' 5-year Total Liabilities high stood at $64.0 million for Q1 2024, and its period low was $5.4 million during Q1 2021.
  • In the last 5 years, Lyra Therapeutics' Total Liabilities had a median value of $29.2 million in 2022 and averaged $37.1 million.
  • As far as peak fluctuations go, Lyra Therapeutics' Total Liabilities skyrocketed by 34890.05% in 2022, and later crashed by 1989.47% in 2025.
  • Over the past 5 years, Lyra Therapeutics' Total Liabilities (Quarter) stood at $20.6 million in 2021, then skyrocketed by 42.15% to $29.2 million in 2022, then soared by 82.04% to $53.2 million in 2023, then grew by 2.96% to $54.8 million in 2024, then decreased by 12.26% to $48.0 million in 2025.
  • Its last three reported values are $48.0 million in Q3 2025, $51.0 million for Q2 2025, and $52.4 million during Q1 2025.